<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">mvjr</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский вестник Юга России</journal-title><trans-title-group xml:lang="en"><trans-title>Medical Herald of the South of Russia</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2219-8075</issn><issn pub-type="epub">2618-7876</issn><publisher><publisher-name>The Rostov State Medical University</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21886/2219-8075-2014-4-54-57</article-id><article-id custom-type="elpub" pub-id-type="custom">mvjr-12</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>ОСОБЕННОСТИ АНТИКОАГУЛЯНТНОЙ ПРОФИЛАКТИКИ ПОСЛЕОПЕРАЦИОННЫХ ВЕНОЗНЫХ ТРОМБОЭМБОЛИЧЕСКИХ ОСЛОЖНЕНИЙ У ОНКОЛОГИЧЕСКИХ БОЛЬНЫХ</article-title><trans-title-group xml:lang="en"><trans-title>FEATURES OF PROPHYLAXIS OF POSTOPERATIVE VENOUS THROMBOEMBOLISM IN ONCOLOGIC PATIENTS</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кательницкий</surname><given-names>И. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Katelnitskyy</surname><given-names>I. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>кафедра хирургических болезней №1</p></bio><bio xml:lang="en"><p>Department of surgical diseases №1</p></bio><email xlink:type="simple">katelnizkji@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кит</surname><given-names>О. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Kit</surname><given-names>O. I.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кательницкая</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Katelnitskaya</surname><given-names>O. V.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Простов</surname><given-names>И. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Prostov</surname><given-names>I. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>кафедра хирургических болезней №1</p></bio><bio xml:lang="en"><p>Department of surgical diseases №1</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Иващенко</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Ivashenko</surname><given-names>A. V.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Туманова</surname><given-names>К. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Tumanova</surname><given-names>K. A.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Ростовский государственный медицинский университет</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Rostov State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Ростовский научно-исследовательский онкологический институт</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Rostov oncological research institute</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>НУЗ ДКБ ОАО РЖД на ст. Ростов-Главный</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Rostov Railway Hospital</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>30</day><month>12</month><year>2014</year></pub-date><volume>0</volume><issue>4</issue><fpage>54</fpage><lpage>57</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Кательницкий И.И., Кит О.И., Кательницкая О.В., Простов И.И., Иващенко А.В., Туманова К.А., 2014</copyright-statement><copyright-year>2014</copyright-year><copyright-holder xml:lang="ru">Кательницкий И.И., Кит О.И., Кательницкая О.В., Простов И.И., Иващенко А.В., Туманова К.А.</copyright-holder><copyright-holder xml:lang="en">Katelnitskyy I.I., Kit O.I., Katelnitskaya O.V., Prostov I.I., Ivashenko A.V., Tumanova K.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.medicalherald.ru/jour/article/view/12">https://www.medicalherald.ru/jour/article/view/12</self-uri><abstract><p>Цель: разработать методы профилактики флеботромбозов у онкологических больных.Материалы и методы: проанализированы результаты лечения 92 пациентов с различными вариантами абдоминального рака. В 1 группу были включены 43 пациента, получавших антикоагулянтную профилактику (эноксапарин 40 мг в подкожно сутки 10 дней). 2 группу составили 49 пациентов, без антикоагулянтов. Контролировали коагулограммуы, Д-димер, печеночные маркеры.Результаты: в 1 группе на 7-10-е сутки выявлен тромбоз подколенной вены в 2 (4,7%) случаях. У двух больных(4,7%) развился варикотромбофлебит. Во 2 группе обнаружен тромбоз бедренно-подколенного сегмента у 5 пациентов (10,2%) и тромбоз поверхностных вен нижних конечностей в 3 наблюдениях (6,1%).Выводы: в целях профилактики ВТЭО (венозных тромбоэмболических осложнений) предпочтительнее использовать низкомолекулярные гепарины. Важен адекватный лабораторный контроль за такими пациентами и подбор индивидуальнойдозы в зависимости от реакции АЧТВ (активированного частичного тромбопластинового времени) на введение стандартной дозы. В особенности это относится к больным при метастатическом поражении печени и распространенных формах рака.</p></abstract><trans-abstract xml:lang="en"><sec><title>Purpose</title><p>Purpose: to study methods of prophylaxis of venous thromboembolism (VTE) in oncologic patients.Materials and methods: results of treatment of 92 patients with various options of an abdominal cancer were analysed. 43 patients (I group) received low-molecular-weight heparin (LMWH) as agent of anticoagulant prevention (enoxaparin 40 mg subcutaneuosly per day for 10 days). The 2nd group was presented by 49 patients, not received anticoagulant therapy. Coagulation profiles, D-dimers and liver function tests were studied.Results: in I group popliteal vein thrombosis was revealed in 2 (4,7%) cases. In two patients (4,7%) varicothromboflebitis was revealed. In 2nd group femoropopliteal thrombosis was diagnosed in 5 patients (10,2%) and thrombosis of superficial veins of lower extremities in 3 patients (6,1%).</p></sec><sec><title>Summary</title><p>Summary: it is more preferable to use LMWH for prevention of VTE. An adequate laboratory control in such patients and selection of an individual dose depends on results of APTT (activated partial thromboplastin time). Especially it concerns to patients with metastatic liver cancer and another groups of high-risk cancer patients.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>онкопациенты</kwd><kwd>флеботромбоз</kwd><kwd>антикоагулянтная терапия</kwd></kwd-group><kwd-group xml:lang="en"><kwd>oncologic patients</kwd><kwd>venous thromboembolism</kwd><kwd>anticoagulant therapy</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Trousseau A. Phlegmasia alba dolens. Lectures on clinical medicine, delivered at the Hotel-Dieu, Paris/ A. Trousseau. – London: New Sydenham Society, 1872. - P.281-295.</mixed-citation><mixed-citation xml:lang="en">Trousseau A. Phlegmasia alba dolens. Lectures on clinical medicine, delivered at the Hotel-Dieu, Paris/ A. Trousseau. – London: New Sydenham Society, 1872. - P.281-295.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Онкология: учеб. для вузов/. Под ред. М. И. Давыдов, Ш. Х. Ганцев. -Москва: ГЭОТАР-Медиа, 2013. -912 с.</mixed-citation><mixed-citation xml:lang="en">Онкология: учеб. для вузов/. Под ред. М. И. Давыдов, Ш. Х. Ганцев. -Москва: ГЭОТАР-Медиа, 2013. -912 с.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Nader Hanna, Kaloyan A., Birkov et al. Impact of venous thromboembolism on mortality of elderly Medicare patients with stage III colon cancer //The Oncologist. – 2012. – V.17. – P. 1191-1197.</mixed-citation><mixed-citation xml:lang="en">Nader Hanna, Kaloyan A., Birkov et al. Impact of venous thromboembolism on mortality of elderly Medicare patients with stage III colon cancer //The Oncologist. – 2012. – V.17. – P. 1191-1197.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Agnelli G, Bolis G, Capussotti L, et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: The @RISTOS project. //Ann Surg. – 2006. – V.243. – P.89–95.</mixed-citation><mixed-citation xml:lang="en">Agnelli G, Bolis G, Capussotti L, et al. A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: The @RISTOS project. //Ann Surg. – 2006. – V.243. – P.89–95.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Нарушения системы гемостаза у онкологических больных / О.А. Тарабрин, А.И. Мазуренко // Достижения биологии и медицины. Одесский национальный медицинский университет. – Одесса. – 2012. – том 1. – №12. – с. 23-25.</mixed-citation><mixed-citation xml:lang="en">Нарушения системы гемостаза у онкологических больных / О.А. Тарабрин, А.И. Мазуренко // Достижения биологии и медицины. Одесский национальный медицинский университет. – Одесса. – 2012. – том 1. – №12. – с. 23-25.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Rasmussen M.C., WilleJorgensen P., Jorgensen L.N. Postoperative fatal pulmonary embolism in a general surgical department// Amer. J. Surg. – 1995. – Vol. 169. – P. 214–216.</mixed-citation><mixed-citation xml:lang="en">Rasmussen M.C., WilleJorgensen P., Jorgensen L.N. Postoperative fatal pulmonary embolism in a general surgical department// Amer. J. Surg. – 1995. – Vol. 169. – P. 214–216.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Gary H. Lyman, Alok A. Khorana, Anna Falanga et al. American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer. //Journal of Clinical Oncology, vol. 25, n 34, 2007. p. 5490- 5505.</mixed-citation><mixed-citation xml:lang="en">Gary H. Lyman, Alok A. Khorana, Anna Falanga et al. American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer. //Journal of Clinical Oncology, vol. 25, n 34, 2007. p. 5490- 5505.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Lyman GH1, Khorana AA, Falanga A. Thrombosis and cancer: emerging data for the practicing oncologist. Am Soc Clin Oncol Educ Book. 2013.oi:1200/EdBook_AM.2013.33.e337.</mixed-citation><mixed-citation xml:lang="en">Lyman GH1, Khorana AA, Falanga A. Thrombosis and cancer: emerging data for the practicing oncologist. Am Soc Clin Oncol Educ Book. 2013.oi:1200/EdBook_AM.2013.33.e337.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Khorana AA, Francis CW, Culakova E, et al. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. //Cancer. – 2007. – V.110. – P. 2339–2346.</mixed-citation><mixed-citation xml:lang="en">Khorana AA, Francis CW, Culakova E, et al. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. //Cancer. – 2007. – V.110. – P. 2339–2346.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
